// App-Quantinova.ai

5064 : Galeterone in treatment-naive patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.

Researchers

Presenter

  • Mary-Ellen Taplin

Principal Investigators

  • Franklin Chu

  • James S. Cochran

  • Karen J. Ferrante

  • David Uri Lipsitz

  • Jennifer Roberts

  • Oliver Sartor

  • Elisabeth I. Heath

Medical Centers

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • San Bernardino Urological Association, San Bernardino, CA

  • Urology Clinics of North Texas, Dallas, TX

  • Tokai Pharmaceuticals, Boston, MA

  • Carolina Urology Partners, Concord, NC

  • Tulane University School of Medicine, New Orleans, LA

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Galeterone

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01709734

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved